Zacks Small Cap Analysis – ARWR: PALISADE Part 3 Outcomes Revealed in NEJM… – Go Well being Professional
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Enterprise Replace Part 3 PALISADE Outcomes Revealed in The New England Journal of Drugs...
Zacks Small Cap Analysis – MNOV: Part 3 ALS Readout in 2025… – Go Well being Professional
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Enterprise Replace Part 3 ALS Trial Ongoing MediciNova, Inc. (NASDAQ:MNOV) is at the moment...
Zacks Small Cap Analysis – NRBO: Information from Half 1 of Part 1 Trial of DA-1726 in 3Q24… – Go Well being Professional
By David Bautz, PhD NASDAQ:NRBO READ THE FULL NRBO RESEARCH REPORT Enterprise Replace SAD Half 1 of Part 1 Trial Information Anticipated in 3Q24 NeuroBo...
Zacks Small Cap Analysis – COCP: Section 1 Single-Ascending Dose Cohort of CDI-988 Exhibits it’s Secure and Nicely Tolerated… – Go Well being Professional
By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Enterprise Replace No Security or Tolerability Points for CDI-988 in SAD Cohorts On July...
Zacks Small Cap Analysis – BCLI: Making ready to Provoke Part 3b Trial of NurOwn Earlier than Finish of 2024… – Go Well being Professional
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Enterprise Replace Able to Transfer Forward with Part 3b Trial for NurOwn in ALS...